View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
October 15, 2013updated 21 Jul 2022 12:29pm

Amedica launches next-generation anterior lumbar interbody spinal fusion device

Amedica has launched its new Valeo II anterior lumbar (AL) interbody fusion device, designed for use with autograft to facilitate intervertebral body fusion of the spine in skeletally mature patients.

By admin-demo

Amedica has launched its new Valeo II anterior lumbar (AL) interbody fusion device, designed for use with autograft to facilitate intervertebral body fusion of the spine in skeletally mature patients.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The Valeo II AL interbody fusion device is made of Silicon Nitride biomaterial, which has been shown to achieve superior new bone growth and osteointegration, along with proven anti-infective properties.

It includes a streamlined, comprehensive instrumentation set designed for ease-of-use.

The new design of the fusion device offers enhanced bone-to-implant interface and resistance to push out when compared with competitive offerings.

Amedica president and CEO Eric K Olson said the company is committed to delivering products that address the changing needs of spinal surgeons.

“Amedica has launched its new Valeo II anterior lumbar (AL) interbody fusion device, designed for use with autograft to facilitate intervertebral body fusion of the spine in skeletally mature patients.”

“As Amedica continues to collaborate with surgeons to develop innovative, safe and effective interbody fusion devices, Silicon Nitride is increasingly becoming the gold standard material for spinal fusion devices,” Olson said.

“With the launch of Valeo II AL, Amedica is positioned to rapidly increase our market share in the $1.6bn interbody fusion device market.”

The next-generation Silicon Nitride AL implants are semi-radiolucent, helping surgeons determine exact placement intra-operatively and improve post-operative monitoring.

Valeo interbody fusion devices do not cause MRI or CT artifacts, which can make imaging interpretation difficult.

According to the company, the success of the Valeo interbody fusion device system proves the safety and effectiveness of Silicon Nitride technology.

The Silicon Nitride AL device provides an optimal environment for bone growth, while reducing the risk for infection due to its innate anti-infective properties.

The Valeo II AL’s inherent advantages help improve the efficacy of spinal fusion procedures resulting in enhanced patient care and better patient outcomes.

According to GlobalData estimates, the spinal fusion market in the US was valued at $3.95bn in 2012 and is expected to grow at a CAGR of 1.9% to reach $4.50bn by 2019.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network